JP2010536896A5 - - Google Patents

Download PDF

Info

Publication number
JP2010536896A5
JP2010536896A5 JP2010522210A JP2010522210A JP2010536896A5 JP 2010536896 A5 JP2010536896 A5 JP 2010536896A5 JP 2010522210 A JP2010522210 A JP 2010522210A JP 2010522210 A JP2010522210 A JP 2010522210A JP 2010536896 A5 JP2010536896 A5 JP 2010536896A5
Authority
JP
Japan
Prior art keywords
leukemia
acute
chronic
lymphocytic leukemia
myeloid leukemia
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2010522210A
Other languages
English (en)
Japanese (ja)
Other versions
JP5524840B2 (ja
JP2010536896A (ja
Filing date
Publication date
Priority claimed from DE102007041115A external-priority patent/DE102007041115A1/de
Application filed filed Critical
Publication of JP2010536896A publication Critical patent/JP2010536896A/ja
Publication of JP2010536896A5 publication Critical patent/JP2010536896A5/ja
Application granted granted Critical
Publication of JP5524840B2 publication Critical patent/JP5524840B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2010522210A 2007-08-30 2008-08-06 チアジアジノン誘導体 Expired - Fee Related JP5524840B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE102007041115A DE102007041115A1 (de) 2007-08-30 2007-08-30 Thiadiazinonderivate
DE102007041115.6 2007-08-30
PCT/EP2008/006466 WO2009030333A1 (de) 2007-08-30 2008-08-06 Thiadiazinonderivate

Publications (3)

Publication Number Publication Date
JP2010536896A JP2010536896A (ja) 2010-12-02
JP2010536896A5 true JP2010536896A5 (enExample) 2014-04-03
JP5524840B2 JP5524840B2 (ja) 2014-06-18

Family

ID=39952448

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2010522210A Expired - Fee Related JP5524840B2 (ja) 2007-08-30 2008-08-06 チアジアジノン誘導体

Country Status (16)

Country Link
US (1) US8211886B2 (enExample)
EP (1) EP2181111B1 (enExample)
JP (1) JP5524840B2 (enExample)
KR (1) KR20100065171A (enExample)
CN (1) CN101784544B (enExample)
AR (1) AR068130A1 (enExample)
AU (1) AU2008295193B2 (enExample)
BR (1) BRPI0816058A2 (enExample)
CA (1) CA2698062C (enExample)
DE (1) DE102007041115A1 (enExample)
EA (1) EA017393B1 (enExample)
ES (1) ES2426356T3 (enExample)
IL (1) IL204127A (enExample)
MX (1) MX2010002096A (enExample)
WO (1) WO2009030333A1 (enExample)
ZA (1) ZA201002218B (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012003338A1 (en) 2010-07-01 2012-01-05 Takeda Pharmaceutical Company Limited COMBINATION OF A cMET INHIBITOR AND AN ANTIBODY TO HGF AND/OR cMET
EP3229836B1 (en) 2014-12-09 2019-11-13 Institut National de la Sante et de la Recherche Medicale (INSERM) Human monoclonal antibodies against axl
WO2016135041A1 (en) 2015-02-26 2016-09-01 INSERM (Institut National de la Santé et de la Recherche Médicale) Fusion proteins and antibodies comprising thereof for promoting apoptosis

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5795964A (en) 1980-12-04 1982-06-15 Morishita Seiyaku Kk Preparation of 2-substituted-3(2h)-pyridazinone derivative
US4397854A (en) 1981-05-14 1983-08-09 Warner-Lambert Company Substituted 6-phenyl-3(2H)-pyridazinones useful as cardiotonic agents
DE4310699A1 (de) 1993-04-01 1994-10-06 Merck Patent Gmbh Thiadiazinone
AU691673B2 (en) 1994-11-14 1998-05-21 Dow Agrosciences Llc Pyridazinones and their use as fungicides
US5635494A (en) 1995-04-21 1997-06-03 Rohm And Haas Company Dihydropyridazinones and pyridazinones and their use as fungicides and insecticides
GB9624482D0 (en) 1995-12-18 1997-01-15 Zeneca Phaema S A Chemical compounds
DE19604388A1 (de) 1996-02-07 1997-08-14 Merck Patent Gmbh Arylalkyl-diazinone
IL125686A (en) 1996-02-13 2002-11-10 Zeneca Ltd Quinazoline derivatives, processes for their preparation, pharmaceutical preparations containing them and their use in the manufacture of a drug with an anti-angiogenic effect and / or an effect of reducing vascular permeability
IL125954A (en) 1996-03-05 2003-06-24 Zeneca Ltd Quinazoline derivatives, processes for their preparation, pharmaceutical compositions containing them and use thereof in the manufacture of medicaments having an antiangiogenic and/or vascular permeability reducing effect
GB9718972D0 (en) 1996-09-25 1997-11-12 Zeneca Ltd Chemical compounds
GB9714249D0 (en) 1997-07-08 1997-09-10 Angiogene Pharm Ltd Vascular damaging agents
AU738595B2 (en) 1997-11-19 2001-09-20 Kowa Co., Ltd. Novel pyridazine derivatives and medicines containing the same as effective ingredients
TWI241295B (en) 1998-03-02 2005-10-11 Kowa Co Pyridazine derivative and medicine containing the same as effect component
GB9900334D0 (en) 1999-01-07 1999-02-24 Angiogene Pharm Ltd Tricylic vascular damaging agents
GB9900752D0 (en) 1999-01-15 1999-03-03 Angiogene Pharm Ltd Benzimidazole vascular damaging agents
JP2003535078A (ja) 2000-05-31 2003-11-25 アストラゼネカ アクチボラグ 血管損傷活性のあるインドール誘導体
RU2003103603A (ru) 2000-07-07 2004-08-20 Энджиоджен Фармасьютикалз Лимитед (Gb) Производные колхинола в качестве ингибиторов ангиогенеза
CA2411160A1 (en) 2000-07-07 2002-01-17 Angiogene Pharmaceuticals Limited Colchinol derivatives as vascular damaging agents
MXPA04003668A (es) 2001-10-31 2004-07-22 Merck Patent Gmbh Inhibidores de fosfodiesteresa de tipo 4 y usos de los mismos.
DE102005055355A1 (de) 2005-11-21 2007-10-31 Merck Patent Gmbh 3,6-Dihydro-2-oxo-6H-[1,3,4]thiadiazinderivate
DE102005055354A1 (de) 2005-11-21 2007-10-31 Merck Patent Gmbh Substituierte 5-Phenyl-3,6-dihydro-2-oxo-6H-[1,3,4]thiadiazine
DE102006037478A1 (de) * 2006-08-10 2008-02-14 Merck Patent Gmbh 2-(Heterocyclylbenzyl)-pyridazinonderivate
DE102007032507A1 (de) * 2007-07-12 2009-04-02 Merck Patent Gmbh Pyridazinonderivate

Similar Documents

Publication Publication Date Title
JP2012513418A5 (enExample)
JP2009039101A5 (enExample)
JP2015513557A5 (enExample)
JP2010532774A5 (enExample)
JP2012501986A5 (enExample)
WO2010017515A3 (en) Breast cancer specific markers and methods of use
WO2009105513A3 (en) Novel compounds and methods for therapy
EP2921177A3 (en) Dual variable domain immunoglobulins and uses thereof
EA201200507A1 (ru) Применение активаторов никотинового ацетилхолинового рецептора альфа 7
TW201206473A (en) Dual variable domain immunoglobulins and uses thereof
PH12013500337A1 (en) Dual variable domain immunoglobulins and uses thereof
PH12013500867A1 (en) Dual variable domain immunoglobulins and uses thereof
JP2009537552A5 (enExample)
WO2009074328A3 (en) Methods and nucleic acids for analyses of lung carcinoma
JP2013074936A5 (enExample)
EP3702782A3 (en) Methods and compositions for amplified electrochemiluminescence detection
JP2012516348A5 (enExample)
WO2009127414A3 (en) Inhibition of angiogenesis and tumor metastasis
EP4279925A3 (en) Dulaglutide for the treatment of chronic kidney disease
JP2010536896A5 (enExample)
JP2011520996A5 (enExample)
JP2009519974A5 (enExample)
JP2008542528A5 (enExample)
JP2009532412A5 (enExample)
WO2011051271A3 (en) Prostate tumor markers and methods of use thereof